ClinicalTrials.gg
Not yet recruitingNCT07322393Updated Apr 30, 2026

Effect of Foot Reflexology On Chemotherapy Induced Nausea and Vomiting in Breast Cancer Patients

An interventional study of Foot Reflexology in Chemotherapy-induced Nausea and Vomiting, sponsored by University of Health Sciences Lahore. Not yet recruiting. Open to female participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-04-30.

Sponsored by University of Health Sciences Lahore · Not applicable, Interventional, and Supportive care

From the registry’s dates

  • Primary completion was expected by Aug 2026, 3 months ago, but the record still lists the study as not yet recruiting.
Phase
Not applicable
Study type
Interventional
Enrollment
50
Allocation
Randomized
Ages
18 Years and older
Sex
Female
01

Study summary

This study aims to evaluate the effect of foot reflexology on chemotherapy-induced nausea and vomiting in breast cancer patients. Nausea and vomiting are common side effects of chemotherapy and can negatively affect patients' comfort and quality of life. Foot reflexology is a non-invasive complementary therapy that involves applying pressure to specific points on the feet. The study will compare patients who receive foot reflexology along with standard care to those who receive standard care alone, to determine whether foot reflexology helps reduce the severity of nausea and vomiting during chemotherapy.

Read the detailed description

This study will be conducted to assess the effectiveness of foot reflexology in reducing chemotherapy-induced nausea and vomiting among breast cancer patients receiving chemotherapy. Eligible participants will be adult breast cancer patients undergoing scheduled chemotherapy treatment.

After enrollment, participants will be randomly assigned into two groups: an experimental group and a control group. The experimental group will receive foot reflexology in addition to standard chemotherapy care, while the control group will receive standard care only.

Foot reflexology will be administered by the researcher using a standardized technique. Each session will last approximately 20-30 minutes and will be provided during chemotherapy sessions across multiple chemotherapy cycles with an interval of 21 days. Reflex points associated with nausea, vomiting, relaxation, and digestion will be stimulated using appropriate pressure techniques.

Nausea and vomiting will be assessed using a standardized assessment tool before and after the intervention during each chemotherapy cycle. The collected data will be analyzed to compare the severity of nausea and vomiting between the experimental and control groups to determine the effectiveness of foot reflexology as a supportive therapy for managing chemotherapy-induced nausea and vomiting.

02

Conditions studied

  • Chemotherapy-induced Nausea and Vomiting

Browse trials for

03

In context

Vomiting

793 studies on the registry are indexed under Vomiting; 99 are open to participants now.

This study's planned enrollment of 50 is below the median of 103 across 673 interventional studies indexed under Vomiting.

Browse Vomiting studies →

Lead sponsor

University of Health Sciences Lahore is the lead sponsor of 83 studies on the registry; 52 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
Female
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

Breast Cancer patients aged >18 Patients receiving chemotherapy in curative setting

Exclusion criteria

Exclusion Criteria:

Patients with paraplegia. Patients with skin ulcers or wounds. Patients with psychiatric conditions. Patients with foot fractures and varicose veins. Patients with GIT and Liver Cancer

05

Study design

Phase
Not applicable
Primary purpose
Supportive care
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
50 participants (estimated)

Study arms

  • Experimental
    Foot Reflexology plus Standard Care

    Participants in this arm will receive foot reflexology in addition to standard chemotherapy care. Foot reflexology will be administered by the researcher using a standardized technique during chemotherapy sessions. Each session will last approximately 20-30 minutes and will be provided during each chemotherapy cycle with a 21-day interval. Standard care will be provided as per hospital protocol.

    Other: Foot Reflexology

  • No intervention
    Standard Care

    Participants in this arm will receive standard chemotherapy care as per hospital protocol. No foot reflexology intervention will be provided.

Interventions

  • OtherFoot Reflexology

    Foot reflexology is a complementary therapy involving the application of pressure to specific reflex points on the feet associated with nausea, vomiting, relaxation, and digestion. The intervention will be administered by the researcher for 20-30 minutes during chemotherapy sessions using a standardized technique.

06

What researchers measure

Primary outcomes

  1. Severity of Chemotherapy-Induced Nausea and Vomiting

    The severity of chemotherapy-induced nausea and vomiting will be assessed using the Rhodes Index of Nausea, Vomiting and Retching (RINVR), a validated scale measuring the frequency, severity, and distress of nausea and vomiting. Scores range from low to high, with higher scores indicating more severe symptoms. Measurements will be recorded before and after the intervention during each chemotherapy cycle.

    Time frame: From baseline to end of each chemotherapy cycle (up to four cycles, 21 days apart)

07

Study locations

No study locations are listed for this record.

08

References and documents

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Apr 30, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07322393
Lead sponsor
University of Health Sciences Lahore
Responsible party
Dania Azher Khan (MSN Student, University of Health Sciences Lahore) — Principal investigator
First posted
Jan 7, 2026
Start date
Jun 1, 2026 (estimated)
Primary completion
Aug 2, 2026 (estimated)
Completion
Sep 1, 2026 (estimated)
Last update
Apr 30, 2026

Study contacts

Dania A Khan, MSN
Contact
asadamzhr93@gmail.com
+923408380021
Nusrat Hussain, MSN
Contact
hussainnusrat640@gmail.com
+9203085182487
DR. Kausar Bano, MBBS, FCPS
study chair · Jinnah Hospital

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Apr 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion